Skip to content
BOE-A-2026-20825 ·7 October 2026 ·orden Medium impact
Administrative

Pharmaceutical laboratories: update of drug reference prices for 2026

Order SND/1053/2026 provides the annual update to the drug reference pricing system within the National Health System. The regulation establishes new groups of medicines, revises prices for existing groups, and removes those that no longer meet legal requirements (Art. 5.1 RD 177/2014). This update serves as a pharmaceutical expenditure control tool to ensure the sustainability of the public healthcare system.

In 3 key points

  1. Annual update of drug reference groups and prices for the 2026 financial year (Orden SND/1053/2026)
  2. Possibility of filing an administrative appeal for reversal within one month before the Minister of Health (art. 123 y 124 de la Ley 39/2015)
  3. Two-month deadline to lodge a contentious-administrative appeal before the National High Court (art. 11 de la Ley 29/1998)

How it affects those involved

For pharmaceutical laboratories and manufacturers, the regulation necessitates a review of margins and selling prices, as new reference prices are set and existing ones are updated (Order SND/1053/2026). Pharmacies and the National Health System will see adjustments in financing and dispensing costs based on the newly approved groups and prices. Affected parties have one month to file an administrative appeal for reversal or two months to lodge a contentious-administrative appeal before the National High Court.

Lifecycle

2026-10-07PublishedPublished in the BOE
2026-10-08Into forceComes into force (Entrada en vigor (nota del analisis oficial del BOE))
Official text Based on BOE data (boe.es). Information, not advice.

Does this provision affect you?

The administrative team reviews your specific situation.

Talk to the administrative team
This analysis is informational only and does not constitute legal advice or create a client-adviser relationship. BMC.
Book your free first meeting